Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
The clinical trial data from SURMOUNT-1 enrolled participants with a mean BMI of 38, and the results showed dramatic weight loss outcomes across dosing tiers
By the end of week four, most patients report noticing genuine weight loss rather than fluid shifts
This is the most plausible explanation for why retatrutide's Phase 2 weight-loss readouts (up to 24.2% at 48 weeks) sit above comparable tirzepatide and semaglutide datasets [3][11]
Never disregard professional medical advice or delay seeking it because of something you have read in this article.
Follow us on social media: JD's Instagram: Will's Instagram: Warrior-Makers page: Join The Community: Peptide of the Week: Womens Hormones, Longevity & Aesthetic Health with Lee Nivinskus Medical Disclaimer: We are not doctors
